Johnson and Johnson outline medical tech growth plan

By Admin
During its annual business review Johnson and Johnson have outlined plans to continue global expansion and market domination within the medical device...

 

During its annual business review Johnson and Johnson have outlined plans to continue global expansion and market domination within the medical devices and diagnostics segment of the company.

Johnson and Johnson’s medical technology division is the largest in the world and accounted for a staggering 41 percent of its total 2012 group sales. The division benefitted from research and development investments of $3.5 billion in the last two years alone.

Following the notable $20 billion takeover of Synthes last year, the global firm will be evaluating strategic options for its Ortho Clinical Diagnostics business in the coming months and will continue to roll out new products to address unmet medical needs, while also taking steps to accelerate growth in Asia-Pacific and other emerging markets.

Alex Gorsky, Chairman and Chief Executive Officer of Johnson and Johnson, said, “We're building on our market leadership positions - having sustained or grown share in the majority of our key platforms - and hold number one or number two positions in over 80 percent of them today.”

This week, the firm also announced its financial results for 2012, during which it generated full-year sales of $67.2 billion - up by 3.4 percent on 2011.Description: DNFCR-8000103-ID-801527105-ADNFCR

Share

Featured Articles

Healthcare Business roundup: Baxter, Sanofi & Eli Lilly

Baxter International to sell kidney care spin-off Vantive; Sanofi's consumer health unit ‘to be separated’; Eli Lilly to buy Morphic Holding for $3.2bn

Trane Technologies Helping US Hospitals Meet Climate Pledge

Christy Fetsch of Trane Technologies explains how the company is helping US hospitals meet White House sustainability pledges for US healthcare provision

Nestlé Health Science Targets Weight Loss Side-Effects

Nestlé Health Science launches nutrition initiative to counteract side effects of weight-loss drugs, including hollowed-out 'Ozempic Face'

Eli Lilly Alzheimer's Drug Kisunla Approved in US by FDA

Medical Devices & Pharma

WEF: Gender Health Gap 'Costs women 75mn years of Life'

Medical Devices & Pharma

Schneider: Swathe of NHS Failing to Measure Sustainability

Sustainability